Scientific article

Rhumatologie : ce qui a changé en 2022

Published inRevue médicale suisse, vol. 19, no. 812, p. 239-242
Publication date2023-02-01

In rheumatology, this year has seen an expansion of knowledge about the treatment of rheumatoid arthritis, with the availability of results from randomized trials evaluating a new molecule targeting IL-6, and regarding the safety profile of tofacitinib compared to TNF-alpha inhibitors. Interesting data on the outcome of pregnancy in patients with spondylarthritis have also been published. New molecules and different treatment strategies have shown promising results in psoriatic arthritis and systemic lupus erythematosus. The utility of botulinum toxin A injections for Raynaud's phenomenon and the efficacy of transplantation of autologous adipose-derived regenerative cells for the treatment of hand dysfunctions have been questioned by 2 randomized controlled trials of patients with systemic sclerosis.

  • Arthritis, Rheumatoid / drug therapy
  • Botulinum Toxins, Type A
  • Humans
  • Lupus Erythematosus, Systemic
  • Rheumatology
  • Scleroderma, Systemic / therapy
Citation (ISO format)
IUDICI, Michele et al. Rhumatologie : ce qui a changé en 2022. In: Revue médicale suisse, 2023, vol. 19, n° 812, p. 239–242. doi: 10.53738/revmed.2023.19.812.239
Main files (1)
Article (Published version)
accessLevelRestrictedaccessLevelPublic 08/02/2024
ISSN of the journal1660-9379

Technical informations

Creation02/03/2023 10:19:46 AM
First validation08/24/2023 3:49:01 PM
Update time08/24/2023 3:49:01 PM
Status update08/24/2023 3:49:01 PM
Last indexation05/06/2024 4:54:29 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack